Keck USC 9th Annual Southern California Kidney Symposium: Updates on Biologics and Novel Therapeutics for Kidney Diseases 2025
$10.00
Video Course · Nephrology · 2025
The 9th annual Keck USC Southern California Kidney Symposium delivers 11 lectures on kidney biologics novel therapeutics — spanning IgA nephropathy treatment, APOL1-mediated CKD, resistant hypertension, hyperphosphatemia management, and immune checkpoint inhibitor nephrotoxicity.
-
11videos
-
USCfaculty
-
2025year
- Novel therapies for IgA nephropathy and membranous nephropathy
- APOL1-mediated CKD from pathways to treatment
- Endothelin inhibition for resistant hypertension
- Immune checkpoint inhibitor-induced AKI
Biologics and novel therapeutics for kidney diseases — from APOL1 targeting to onco-nephrology
The 9th annual Keck USC Southern California Kidney Symposium presents 11 lectures on kidney biologics novel therapeutics, bringing together faculty from USC and other U.S. academic institutions to cover new management strategies in hypertension, advanced CKD, glomerular disease, and kidney transplantation. Sessions address emerging therapies across multiple domains — from endothelin inhibition for resistant hypertension and hypoxia-inducible factor activation for CKD anemia, to emerging biologics for antibody-mediated transplant rejection and immune checkpoint inhibitor nephrotoxicity.
-
11video lectures
-
USCand multi-center faculty
-
2025edition
Inside this resource
Glomerular disease biologics — IgA, membranous, lupus, and C3
Four lectures address the expanding therapeutic landscape for glomerular diseases. Faculty compare emerging IgA nephropathy therapies, outline new diagnostic and treatment approaches for membranous nephropathy, review expanded targets for lupus nephritis, and discuss genetic factors and therapeutic options for C3 glomerulopathy. Each session emphasizes practical treatment selection among competing agents.
CKD therapeutics — hypertension, anemia, and hyperphosphatemia
Novel management strategies extend beyond glomerular disease. Sessions cover endothelin inhibition as a new option for resistant hypertension, hypoxia-inducible factor activation for CKD-related anemia, and emerging therapies for hyperphosphatemia in ESKD patients. Faculty compare these new agents with established therapies, highlighting strengths and limitations of each approach.
APOL1 kidney disease and transplant biologics
A dedicated session traces APOL1-mediated kidney disease from molecular pathways to therapeutic options currently in development. On the transplant side, emerging biologics for antibody-mediated rejection receive focused coverage. The program also addresses immune checkpoint inhibitor-induced AKI — a rapidly growing area as cancer immunotherapy expands.
Who this serves
- Nephrologists — practical updates on biologics and novel therapeutics across kidney disease domains
- Hospitalists and internists — co-managing patients with renal complications on newer agents
- Researchers and fellows — translating cutting-edge science into clinical practice
The chart
| Format | Video Course · 11 lectures |
|---|---|
| Location | Aresty Conference Center, USC Health Sciences Campus, Los Angeles |
| Publisher | Keck School of Medicine of USC |
| Department | Nephrology |
| Delivery | Instant download after checkout · lifetime re-access |
Verified original fileInstant downloadEncrypted checkout
6 reviews for Keck USC 9th Annual Southern California Kidney Symposium: Updates on Biologics and Novel Therapeutics for Kidney Diseases 2025
Add a review
Related products
Nephrology
Nephrology
Steven W. –
Strong symposium with real clinical applications. The onco-nephrology and transplant biologics sessions were the standout lectures for my practice.
Carlos D. –
Some lectures feel rushed — the 11-topic format means each gets limited time. Content quality is high throughout, but a deeper dive on 6-8 topics would serve better.
Emily R. –
Exactly the kind of translational update I needed. The immune checkpoint inhibitor AKI session was particularly relevant with the growing use of these agents.
Hassan A. –
Good breadth across multiple therapeutic areas. The endothelin inhibition lecture was a highlight. Wished for slightly more depth on the C3 glomerulopathy genetics session.
Jessica L. –
The APOL1 session was outstanding — finally a clear path from molecular pathways to bedside treatment options. The IgA nephropathy comparison was equally strong.
Nicole F. –
Practical and clinically relevant. The hyperphosphatemia and anemia sessions gave me new options to discuss with my dialysis patients. Well worth the price.